Cardax Return on Equity

Cardax (CDXI) currently reports a ROE of 67.67%. That is above the Healthcare sector average of 11.15%. Use the charts on this page to explore Cardax's ROE history and peer comparisons.

Cardax's ROE of 67.67% is higher than the Healthcare sector average of 11.15%. That is roughly 506.7% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Cardax's current 67.67% should be judged against Healthcare norms (sector average: 11.15%) and against CDXI's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 67.67%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 11.15%. From there, open related valuation or income-statement pages for Cardax, and consider following CDXI for alerts when major investors trade the stock.

Cardax is classified in the Healthcare sector. On ROE, it currently shows 67.67% versus a sector average near 11.15%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CDXI with unrelated industries.